Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people.
Crohn's Disease Research Studies
Investigators
Open Research Studies for Crohn's Disease
Diversity
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Filgotinib (Oral)
Possibility of Placebo: 1 in 3
Interested in this study? Please contact the coordinator below:
Tonika Peterson
(317) 278-9135
Galaxi
Duration: 48 weeks + potential to receive up to 2 additional years of treatment
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Guselkumab or Ustekinumab ( IV + Subcutaneous)
Possibility of Placebo: 1 in 5
Tonika Peterson
(317) 278-9135
Non-Invasive Vagal Nerve Stimulation in Crohn's Disease
Duration: 16 weeks
Patient Population: Adult patients with mild to moderate Crohn's Disease and on a stable dose of medication
Study Intervention: 3 self-provided vagal nerve stimulations per day for 16 weeks
Possibility of Placebo: None
Interested in this study? Please contact the coordinator below:
Neeley Dukles
(317) 278-9238
SPARC IBD
Enrolling: Yes
Principle Investigator: Matthew Bohm, DO
Duration: All bio-specimen collections and chart reviews will continue until 2026
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Intervention: Medical chart reviews and biological specimen collection.
Interested in this study? Please contact the coordinator below:
Teresa Arnold
(317) 278-0609
VIVID - 1
Duration: 1 year – Option to roll into the long term extension study VIVID-2
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Mirikizumab vs Stelara vs Placebo
Possibility of Placebo: 2 in 11
Interested in this study? Please contact the coordinator below:
Tonika Peterson
(317) 278-9135
IBD QORUS
Duration: Indefinate or upon withdraw
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Procedures: Patient surveys before every office visit & medical chart reviews
Interested in this study? Please contact the coordinator below:
Neeley Dukles
(317) 278-9238
Lattice
Duration: Approximately 112 weeks
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: BMS-986165 (oral)
Possibility of Placebo: 1 in 4
Interested in this study? Please contact the coordinator below:
Debbie Drenzyk
(317) 278-9226
Closed Crohn's Disease Studies
-
Yellowstone
Principle Investigator: Monika Fischer, MD
Duration: 12 Weeks + potential to receive treatment for up to 4.5 years
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Ozanimod (Oral)
Possibility of Placebo: 1 in 3